Senior Associate Scientist- Small Molecule Bioanalysis - San Francisco, CA | Biospace
Get Our FREE Industry eNewsletter

Senior Associate Scientist- Small Molecule Bioanalysis


San Francisco, CA
Posted Date:
Position Type:
Full time
Job Code:
Required Education:
Bachelors Degree
Areas of Expertise Desired:

Job Description

Amgen, South San Francisco is seeking a highly motivated and team-oriented candidate for the position of Senior Associate Scientist in the Pharmacokinetics and Drug Metabolism (PKDM) Department. The Senior Associate Scientist will be part of a multi-function group to support discovery programs across several therapeutic areas.


Under minimal supervision, provide small molecule bioanalytical support for PK, PD, and TK studies using cutting edge LC-MS/MS platforms.

With appropriate guidance, contribute to LC-MS based bioanalytical support of therapeutic proteins, peptides and other molecule types.

Participate in evaluation and application of new technologies that can be implemented in the routine workflow.

Work independently to plan and execute experiments and interpret results.


Basic Qualifications:

Master's degree & 3 years of scientific experience
Bachelor's degree & 5 years of scientific experience

Preferred Qualifications:

BS/MS in chemistry, bioanalytical chemistry, or related field

2 + years relevant bioanalytical experience using LC-MS/MS

Proven ability to operate and troubleshoot triple-quadrupole mass spectrometers and HPLC

Demonstrate good analytical skills, and have a basic knowledge of pharmacokinetics and drug metabolism

Good oral and written communication abilities, excellent time-management and multi-tasking skills, and the ability to work cooperatively in a team environment

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.